Stock listing

OTC:BIOQ BIOQUAL, Inc. Stock

Follow BIOQUAL, Inc. into a list and get an email when it puts out news.

Share price · OTC:BIOQ

$30.00 USD 0.00 (0.0%)

Close on Nov 20, 2026

Past year -22.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$30.00 – $30.00 USDNov 20, 2026
Volume
471 sharesNov 20, 2026
Market cap
$26.83M USDAt the close on Nov 20, 2026 · price × 894,416 shares outstanding
52-week range
$30.00 – $38.51 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5,590 USDMedian day 0 shares · 38 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
BIOQUAL, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:BIOQ · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$30.000.000.0%$30.00$30.00$30.00471
$30.00-1.00-3.2%$30.00$30.00$30.00100
$31.00+0.36+1.2%$31.00$31.00$31.00100
$30.640.000.0%$30.64$30.64$30.640
$30.640.000.0%$30.64$30.64$30.640
$30.64-2.36-7.2%$32.90$32.90$30.64900
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.001,095
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.001,095
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.001,095
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.001,095
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.000
$33.000.000.0%$33.00$33.00$33.001,100
$33.000.000.0%$33.00$33.00$33.001,272
$33.000.000.0%$33.00$33.00$33.000
$33.00+0.50+1.5%$33.00$33.00$33.00100
$32.500.000.0%$32.50$32.50$32.500
$32.500.000.0%$32.50$32.50$32.500
$32.500.000.0%$32.50$32.50$32.500
$32.500.000.0%$32.50$32.50$32.500

Splits

1 split · OTC:BIOQ · every price before a split is adjusted for it

DayRatioWhat
1-for-6Consolidation
Ticker
OTC:BIOQ
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
OTC
Currency
USD

What changed lately

Latest news

All BIOQUAL, Inc. news

BIOQUAL, Inc. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
5 in the last 12 months · 50 in all · newest Oct 22, 2026 · oldest 2018

Valuation

EV/sales 1.1× against a median of 2.4×: 3rd lowest of 10 Diagnostics & research services companies shown. Statements: 4 quarters to Aug 31, 2026 · price Nov 20, 2026

Enterprise value
$42.28M USD
P/E
Loss
EV/sales
1.1×
EV/EBITDA
Negative EBITDA
Price/book
0.8×
Gross margin
2.6%
Operating margin
−11.8%
Net margin
−11.0%
Debt to equity
1.0×
Beta vs S&P 500
-0.01

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BIOQUAL, Inc. · OTC:BIOQUS$26.83MUS$42.28Mn/a1.1×n/a0.8×−11.0%1.0×-0.01
Abingdon Health PLC · LSE:ABDXUS$28.10MUS$26.11Mn/a1.8×n/a3.5×−19.4%0.2×n/a
MedMira Inc. · TSXV:MIRUS$26.91MUS$27.23Mn/a105×n/an/a−808.2%n/a0.29
Ikonisys SA · EURONEXT:ALIKOUS$26.75MUS$31.11Mn/a20.4×n/a1.3×−302.8%0.3×n/a
Interpace Biosciences, Inc. · OTC:IDXGUS$26.56MUS$23.63M1.2×0.6×21.0×1.1×58.1%0.0×-0.33
Microbix Biosystems Inc. · TSX:MBXUS$26.27MUS$25.96Mn/a2.4×n/a1.6×−31.7%0.3×0.03
Bioptic Inc. · TPEX:6850US$26.10MUS$22.55Mn/an/an/a2.0×n/a0.2×n/a
genOway SA · EURONEXT:ALGENUS$25.86MUS$38.95M25.4×1.7×8.7×1.1×4.4%0.7×n/a
Orientbio, Inc. · KRX:002630US$25.17M−US$3.29M14.6×−0.1×−0.8×0.5×8.1%0.0×n/a
Genesystem Co., Ltd. · KRX:363250US$24.68MUS$22.48Mn/a29.8×n/a2.8×n/a0.2×n/a
Clever Culture Systems Limited · ASX:CC5US$24.56MUS$25.41Mn/a8.3×n/a4.9×−48.4%0.4×n/a
Median of the othersUS$26.18MUS$25.68M14.6×2.4×8.7×1.6×−25.5%0.2×0.03

Team and board

OfficerRole
Chris KirkChief Financial Officer
Hanne Andersen ElyardPresident, Chief Scientific Officer
Mitch FranklinChief Operating Officer
Anthony CookVice President of Veterinary Services
Jim TreeceVice President of Operations
Swagata KarVice President, Preclinical Models and Services

Events

QuarterResultsShare move
Q2 2026Jan 22, 20260.0%
Q1 2026Sep 18, 2025 · Before open0.0%
Q3 2025Apr 21, 2025 · Before open
Q2 2025Jan 21, 2025 · Before open
Q1 2025Oct 22, 2024 · After close
Q3 2024Apr 22, 2024 · After close
Q2 2024Jan 23, 2024 · After close
Q1 2024Oct 20, 2023 · Before open
Q3 2023Apr 21, 2023 · After close−7.3%
Q2 2023Jan 20, 2023 · After close
All 17 quarters
QuarterResultsShare move
Q1 2023Oct 21, 2022 · After close
Q3 2022Apr 21, 2022 · After close−5.9%
Q2 2022Jan 21, 2022 · After close−6.3%
Quarter to Aug 31, 2021Sep 17, 2021
Quarter to May 31, 2021Aug 31, 2021
Quarter to Feb 28, 2021Apr 21, 2021
Quarter to Nov 30, 2020Jan 22, 2021+1.8%

Open Events

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue39.9M48.9M58.6M62.7M66.2M57.7M46.4M39.5M35.9M36.6M
Cost of revenue38.5M50.8M51.2M50.1M53.1M43.7M36.7M32.1M27.2M26.7M
Gross profit1.43M-1.90M7.43M12.6M13.0M14.0M9.69M7.41M8.73M9.90M
Research and development541.0K806.0K1.11M828.8K1.13M331.5K331.5K334.0K
Selling, general and administrative7.45M7.54M6.47M5.42M4.37M3.83M3.45M3.36M
Operating income-4.47M-1.90M-19.6K1.10M6.53M8.56M5.32M3.58M5.27M6.54M
Depreciation and amortization2.22M2.37M2.56M5.83M8.19M4.46M4.28M872.3K741.5K625.2K
EBITDA-2.25M474.0K2.54M6.94M14.7M13.0M9.60M4.46M6.01M7.17M
Interest expense010.5K049.3K68.5K
Income before tax-3.72M-1.29M476.4K1.13M6.58M8.62M5.49M3.71M5.29M6.49M
Income tax452.5K-238.4K-7.03K297.7K1.32M2.29M1.26M878.4K1.62M2.52M
Net income-4.17M-1.05M483.5K835.5K5.26M6.33M4.23M2.83M3.66M3.96M
Earnings per share, basic-4.66-1.170.540.935.887.084.733.174.104.44

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents11.1M17.9M15.6M7.28M2.18M7.72M10.3M9.21M10.2M9.29M
Short-term investments4.89M
Receivables10.5M13.2M14.0M21.3M26.8M20.1M14.6M11.5M9.69M8.35M
Inventory11111
Current assets26.8M31.3M30.9M29.9M31.7M29.3M26.3M21.3M20.3M17.9M
Property, plant and equipment30.3M30.6M23.0M21.5M5.29M4.29M2.95M
Goodwill1.03M1.03M1.03M1.03M1.03M1.03M1.03M1.03M1.03M1.03M
Total assets68.4M57.1M56.6M61.3M63.3M53.4M49.5M28.3M26.3M22.8M
Accounts payable1.04M1.90M1.38M1.59M3.29M2.11M2.48M1.31M1.80M1.24M
Current liabilities6.36M8.42M7.69M8.30M9.77M8.52M7.68M2.78M3.46M3.10M
Long-term debt250.1K
Total debt32.7M16.5M3.59M18.6M18.7M14.6M16.1M250.1K567.3K
Total liabilities36.0M21.0M18.9M23.7M25.7M19.9M21.4M3.75M4.26M3.84M
Shareholders' equity32.4M36.2M37.6M37.6M37.7M33.5M28.2M24.6M22.0M18.9M
Shares outstanding894.4K894.4K894.4K894.4K894.4K894.1K894.0K893.7K893.7K893.4K

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations351.4K2.94M9.36M8.23M313.4K2.15M4.08M1.70M3.71M5.39M
Capital spending-418.2K-238.8K-597.1K-2.24M-4.89M-4.41M-2.40M-1.87M-2.07M-741.8K
Free cash flow-66.8K2.71M8.76M5.99M-4.57M-2.26M1.67M-169.6K1.64M4.65M
Cash from investing-7.08M-238.8K-597.1K-2.24M-4.73M-3.70M-2.40M-1.86M-1.98M-578.5K
Cash from financing-447.2K-447.2K-894.4K-1.12M-983.9K-626.1K-786.8K-853.3K-704.8K
Dividends paid-447.2K-447.2K-894.4K-1.12M-983.9K-626.1K-536.6K-536.0K-402.0K
Change in cash-6.73M2.26M8.31M5.10M-5.54M-2.54M1.05M-953.0K872.2K4.11M

Open Financials

Cap table

Built by 6ix from BIOQUAL, Inc.’s releases

Common shares
894,416
Fully diluted
894,416

Fully diluted

LineShares
Common shares894,416

Share count over time

CountShares
Nov 22, 2026894,416

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anthony CookVice President of Veterinary Services · Since at least Nov 5, 2026
Chris KirkChief Financial Officer · Since at least Nov 4, 2026
Hanne Andersen ElyardPresident, Chief Scientific Officer · Since at least Apr 30, 2025
Jim TreeceVice President of Operations · Since at least Nov 4, 2026
Mitch FranklinChief Operating Officer · Since at least Nov 4, 2026
Swagata KarVice President, Preclinical Models and Services · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about BIOQUAL, Inc.